TP53 and myelodysplastic syndrome: A Phase 3, placebo-controlled trial of magrolimab in combination with AZA (ENHANCE; NCT04313881) is ongoing, and preliminary data showed CR of 40% in TP53-mutants higher-risk MDS [109, 110].